Welcome to our dedicated page for Hologic SEC filings (Ticker: HOLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hologic, Inc. (Nasdaq: HOLX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC, Hologic submits periodic and current reports that offer detailed insight into its operations, financial performance and material corporate events.
Among the most closely watched documents for Hologic are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s diagnostics, breast health, GYN surgical and skeletal health businesses, outline risk factors and discuss segment performance. Current reports on Form 8-K provide timely updates on specific events, such as quarterly earnings releases, changes to executive compensation arrangements and material transactions.
Recent 8-K filings have included the announcement of financial results for the fourth quarter of fiscal 2025, along with reconciliations of non-GAAP measures such as adjusted EBITDA and non-GAAP EPS, and the disclosure of a revised form of restricted stock unit award agreement approved by the Compensation Committee. Another 8-K details the Agreement and Plan of Merger under which a merger subsidiary affiliated with funds managed by Blackstone and TPG will merge with and into Hologic, with Hologic surviving as a wholly owned subsidiary of a parent entity. That filing also notes that, if the merger is consummated, Hologic’s common stock will be delisted from Nasdaq and deregistered under the Exchange Act.
On this page, users can review Hologic’s 8-K filings related to transaction announcements, executive employment agreement amendments and results of operations, alongside its periodic reports when available. These filings help investors understand how Hologic’s diagnostics, breast health, GYN surgical and skeletal health segments contribute to overall results, how non-GAAP metrics are defined, and how material agreements—such as the proposed merger with Blackstone- and TPG-affiliated entities—may affect the company’s capital structure and listing status.
Stock Titan enhances access to these documents by pairing them with AI-powered summaries that explain key points in plain language. This can be especially helpful for lengthy filings like 10-K and 10-Q reports, as well as complex transaction-related 8-Ks. Users interested in HOLX can use this page to monitor new filings as they appear on EDGAR, review historical disclosures and track how Hologic’s regulatory reporting reflects developments in its medical technology and women’s health businesses.
Hologic, Inc. executive Jan Verstreken reported changes to his equity awards in connection with the company’s closing merger with Hopper Parent Inc. At the merger’s effective time, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right worth up to $3.00 in cash, if payable. Outstanding stock options, restricted stock units and performance stock units held by Verstreken were cancelled or converted into cash- and CVR-based rights consistent with this merger consideration. As a result of the transaction, he no longer beneficially owns any shares of Hologic common stock.
Hologic Inc. reported that Brandon Schnittker, President, GYN Surgical, had his equity awards settled in connection with the company’s merger into a wholly owned subsidiary of Hopper Parent Inc. Each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right (CVR) for up to an additional $3.00 in cash.
Multiple non-qualified stock options, performance stock units and 17,644 shares of common stock were disposed of to the issuer, and performance stock units were certified and then converted into the cash-and-CVR merger consideration. As a result of the merger, Schnittker no longer beneficially owns any Hologic common stock, directly or indirectly.
Hologic Inc President, Diagnostic Solutions Jennifer M. Schneiders reported multiple equity award adjustments tied to the company’s merger. On April 7, 2026, she disposed of 41,462 shares of common stock back to the issuer and surrendered several non-qualified stock option grants covering 3,804, 4,058, 10,028 and 18,698 underlying shares.
Footnotes state that, under the October 21, 2025 merger agreement, each Hologic common share was converted into the right to receive $76.00 in cash plus a contingent value right of up to $3.00 in cash per share. Restricted stock units and performance stock units were converted into cash- and CVR-based rights and then cancelled. As a result of the merger, Schneiders no longer beneficially owns any Hologic common stock.
Hologic Inc.’s Chief Financial Officer Karleen Oberton reported the cash-out of her equity awards in connection with Hologic’s merger with Hopper Parent Inc. At the merger’s effective time, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right (CVR) representing up to an additional $3.00 in cash.
On the same date, Oberton disposed of multiple non‑qualified stock option grants covering tens of thousands of shares at exercise prices between $45.61 and $79.39, as well as performance stock units and 150,735 shares of common stock back to the issuer. A performance‑based award of 42,707 performance stock units was certified and then cancelled for the merger consideration. As a result of the merger, she no longer beneficially owns any Hologic common stock, with her equity position replaced by the cash and CVR rights defined in the merger agreement.
Hologic, Inc. Chief Operating Officer Mitchell D. Essex reported merger-related equity changes tied to the company’s acquisition. On April 7, 2026, his non‑qualified stock options covering 2,972, 11,596, 25,070 and 32,722 shares of common stock were disposed of back to the issuer, ending those option positions.
The filing also shows 46,154 performance stock units certified and then cancelled, and 77,694 shares of common stock disposed to the issuer at the merger’s effective time. Under the merger terms, each Hologic common share was converted into the right to receive $76.00 in cash plus a contingent value right for up to $3.00 in cash per share. As a result of these transactions, Essex no longer beneficially owns any Hologic common stock.
Hologic, Inc. completed a merger in which Hopper Merger Sub combined with the company, making Hologic a wholly owned subsidiary of Hopper Parent Inc. At the effective time, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right for up to an additional $3.00 in cash per share.
For General Counsel Anne M. Liddy, all outstanding stock options, performance stock units, restricted stock units, and 28,052 shares of common stock were disposed of to the issuer or converted into rights to receive the merger consideration. As a result of the merger, she no longer beneficially owns any Hologic common stock.
Hologic Inc. executive Mark W. Horvath has exited all company equity as part of a completed cash merger. On April 7, 2026, he disposed of 23,026 shares of Hologic common stock back to the company, along with multiple non-qualified stock options and performance stock units.
The option awards covering a total of 20,596 underlying shares at exercise prices ranging from $65.24 to $79.39 were canceled and converted into the merger consideration. In addition, 7,762 performance stock units were certified by the board’s compensation committee and then canceled for the same merger consideration.
Under the merger, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right that can pay up to $3.00 in cash. Following these transactions, Horvath no longer beneficially owns any Hologic common stock, and the dispositions reflect payouts under the merger agreement rather than open-market trading.